These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35166607)

  • 1. Description of damage in different clusters of patients with antiphospholipid syndrome.
    Uludağ Ö; Çene E; Gurel E; Çetin Ç; Bektaş M; Yalçınkaya Y; Diz-Küçükkaya R; Gül A; Inanç M; Artim-Esen B
    Lupus; 2022 Apr; 31(4):433-442. PubMed ID: 35166607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus.
    Torricelli AK; Ugolini-Lopes MR; Bonfá E; Andrade D
    Lupus; 2020 Mar; 29(3):256-262. PubMed ID: 31986962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
    Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
    J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome.
    Grika EP; Ziakas PD; Zintzaras E; Moutsopoulos HM; Vlachoyiannopoulos PG
    J Rheumatol; 2012 Mar; 39(3):516-23. PubMed ID: 22247356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey.
    Uludağ Ö; Bektaş M; Çene E; Sezer M; Şahinkaya Y; Gül A; Inanç M; Öcal L; Artim-Esen B
    J Thromb Thrombolysis; 2021 Feb; 51(2):466-474. PubMed ID: 32588289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study.
    Guedon AF; Ricard L; Laurent C; De Moreuil C; Urbanski G; Deriaz S; Gerotziafas G; Elalamy I; Audemard A; Chasset F; Alamowitch S; Sellam J; Boffa JJ; Cohen A; Wahl C; Abisror N; Maillot F; Fain O; Mekinian A
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36894193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus.
    Ruiz-Irastorza G; Egurbide MV; Ugalde J; Aguirre C
    Arch Intern Med; 2004 Jan; 164(1):77-82. PubMed ID: 14718326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study.
    Qi W; Zhao J; Huang C; Jiang N; Li J; Wu C; Zhang S; Hu C; Xu D; Wang Q; Li M; Tian X; Zhao Y; Zeng X
    Arthritis Res Ther; 2022 Jun; 24(1):140. PubMed ID: 35690831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?
    Gómez-Puerta JA; Martín H; Amigo MC; Aguirre MA; Camps MT; Cuadrado MJ; Hughes GRV; Khamashta MA
    Medicine (Baltimore); 2005 Jul; 84(4):225-230. PubMed ID: 16010207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome: A multicenter study with 1519 patients.
    Islabão AG; Mota LMH; Ribeiro MCM; Arabi TM; Cividatti GN; Queiroz LB; Andrade DC; Sakamoto AP; Trindade VC; Novak GV; Molinari BC; Campos LM; Aikawa NE; Pereira RMR; Terreri MT; Magalhães CS; Marini R; Gomes HR; Silva MF; Oliveira SK; Sztajnbok FR; Sacchetti SB; Bica BE; Sena EG; Moraes AP; Santos MC; Robazzi TC; Spelling PF; Scheibel IM; Cavalcanti AS; Naka EN; Guimarães LJ; Santos FP; Sampaio MC; Bonfá E; Silva CA;
    Autoimmun Rev; 2020 Dec; 19(12):102693. PubMed ID: 33164791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality.
    Riancho-Zarrabeitia L; Martínez-Taboada V; Rúa-Figueroa I; Alonso F; Galindo-Izquierdo M; Ovalles J; Olivé-Marqués A; Fernández-Nebro A; Calvo-Alén J; Menor-Almagro R; Tomero-Muriel E; Uriarte-Isacelaya E; Botenau A; Andres M; Freire-González M; Santos Soler G; Ruiz-Lucea E; Ibáñez-Barceló M; Castellví I; Galisteo C; Quevedo Vila V; Raya E; Narváez-García J; Expósito L; Hernández-Beriaín JA; Horcada L; Aurrecoechea E; Pego-Reigosa JM
    Lupus; 2020 Oct; 29(12):1556-1565. PubMed ID: 32807021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series.
    Madison JA; Gockman K; Hoy C; Tambralli A; Zuo Y; Knight JS
    Pediatr Rheumatol Online J; 2022 Feb; 20(1):17. PubMed ID: 35197077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for arterial thrombosis in antiphospholipid syndrome.
    Matyja-Bednarczyk A; Swadźba J; Iwaniec T; Sanak M; Dziedzina S; Ćmiel A; Musiał J
    Thromb Res; 2014 Feb; 133(2):173-6. PubMed ID: 24321419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiphospholipid syndrome in patients with systemic lupus erythematosus.
    Pons-Estel GJ; Andreoli L; Scanzi F; Cervera R; Tincani A
    J Autoimmun; 2017 Jan; 76():10-20. PubMed ID: 27776934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients.
    Ramos-Casals M; Campoamor MT; Chamorro A; Salvador G; Segura S; Botero JC; Yagüe J; Cervera R; Ingelmo M; Font J
    Lupus; 2004; 13(10):777-83. PubMed ID: 15540510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome.
    Muñoz-Rodríguez FJ; Reverter JC; Font J; Tàssies D; Cervera R; Espinosa G; Carmona F; Balasch J; Ordinas A; Ingelmo M
    Haematologica; 2000 Jun; 85(6):632-7. PubMed ID: 10870121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS).
    Amigo MC; Goycochea-Robles MV; Espinosa-Cuervo G; Medina G; Barragán-Garfias JA; Vargas A; Jara LJ
    Lupus; 2015 Aug; 24(9):927-34. PubMed ID: 25767071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of the antiphospholipid syndrome and its effect on survival in 679 Chinese patients with systemic lupus erythematosus: a cohort study.
    Mok CC; Chan PT; Ho LY; Yu KL; To CH
    Medicine (Baltimore); 2013 Jul; 92(4):217-222. PubMed ID: 23793109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.